Our proprietary Flycode® technology and antibody discovery platform is our competitive advantage. It enables exploring untapped opportunities for large molecules and proteins as well as conjugates of small, RNA and DNA molecules that need better targeting.
In-house, we leverage our technologies and expertise to create a pipeline of drug candidates. We engage in multiple drug development programs in therapeutic areas of need and in indications with a necessity for improved tissue-specific delivery. We aim at first-in-class or best-in-class precision medicines and seek for strategic partnerships with global pharmaceutical and biotech companies after reaching pivotal points of drug development.